14-day Premium Trial Subscription Sign Up For FreeGet Free

CytRx Corporation Stock Forecast NASDAQ:CYTR

$0.50 (-5.66%)

Volume: 2k

Closed: Jan 26, 2022

Hollow Logo Score: -3.442

CytRx Corporation Stock Forecast

$0.50 (-5.66%)

Volume: 2k

Closed: Jan 26, 2022

Score Hollow Logo -3.442

CytRx Corporation Company Profile

11726 San Vicente Boulevard

Los Angeles CA 90049



Industry: Biotechnology

Sector: Healthcare

CytRx Corporation


CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company’s product candidate is aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi's sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with STS; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It also has completed Phase IIb and Phase Ib/II clinical trials with aldoxorubicin as a first-line therapy for STS; a Phase Ib clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors; and a Phase Ib pharmacokinetics clinical trial in patients with metastatic solid tumors. The company is also developing DK049 that is in pre-clinical stage used as anti-cancer drug conjugate. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE